WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H464266
CAS#: Risuteganib trifluoroacetate salt
Description: Risuteganib is an anti-integrin peptide and a derivative of RGD peptide.
Hodoodo Cat#: H464266
Name: Risuteganib trifluoroacetate salt
CAS#: Risuteganib trifluoroacetate salt
Chemical Formula: C24H40F3N9O13S
Exact Mass: 0.00
Molecular Weight: 751.690
Elemental Analysis: C, 38.35; H, 5.36; F, 7.58; N, 16.77; O, 27.67; S, 4.27
Related CAS #: 1307293-62-4 (free base) Risuteganib TFA
Synonym: Risuteganib TFA salt; ALG-1001; ALG1001; ALG 1001;
IUPAC/Chemical Name: glycyl-L-arginylglycyl(sulfo)-D-alanyl-L-threonyl-L-proline compound with 2,2,2-trifluoroacetic acid (1:1)
InChi Key: WLTGXURCDLTUBR-CIEQAUARSA-N
InChi Code: InChI=1S/C22H39N9O11S.C2HF3O2/c1-11(32)17(20(37)31-7-3-5-14(31)21(38)39)30-19(36)13(10-43(40,41)42)29-16(34)9-27-18(35)12(28-15(33)8-23)4-2-6-26-22(24)25;3-2(4,5)1(6)7/h11-14,17,32H,2-10,23H2,1H3,(H,27,35)(H,28,33)(H,29,34)(H,30,36)(H,38,39)(H4,24,25,26)(H,40,41,42);(H,6,7)/t11-,12+,13+,14+,17+;/m1./s1
SMILES Code: N=C(NCCC[C@@H](C(NCC(N[C@H](C(N[C@H](C(N1[C@H](C(O)=O)CCC1)=O)[C@@H](C)O)=O)CS(O)(=O)=O)=O)=O)NC(CN)=O)N.OC(C(F)(F)F)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 751.69 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Samanta A, Aziz AA, Jhingan M, Singh SR, Khanani AM, Chhablani J. Emerging Therapies in Nonexudative Age-Related Macular Degeneration in 2020. Asia Pac J Ophthalmol (Phila). 2021 Jan 28. doi: 10.1097/APO.0000000000000355. Epub ahead of print. PMID: 33512911.
2: Schneider K, Chwa M, Atilano SR, Shao Z, Park J, Karageozian H, Karageozian V, Kenney MC. Differential effects of risuteganib and bevacizumab on AMD cybrid cells. Exp Eye Res. 2021 Feb;203:108287. doi: 10.1016/j.exer.2020.108287. Epub 2020 Oct 16. PMID: 33075294.
3: Yang P, Shao Z, Besley NA, Neal SE, Buehne KL, Park J, Karageozian H, Karageozian V, Ryde IT, Meyer JN, Jaffe GJ. Risuteganib Protects against Hydroquinone-induced Injury in Human RPE Cells. Invest Ophthalmol Vis Sci. 2020 Aug 3;61(10):35. doi: 10.1167/iovs.61.10.35. PMID: 32818234; PMCID: PMC7443126.
4: Bhatwadekar AD, Kansara V, Luo Q, Ciulla T. Anti-integrin therapy for retinovascular diseases. Expert Opin Investig Drugs. 2020 Sep;29(9):935-945. doi: 10.1080/13543784.2020.1795639. Epub 2020 Sep 9. PMID: 32657172.
5: Shaw LT, Mackin A, Shah R, Jain S, Jain P, Nayak R, Hariprasad SM. Risuteganib-a novel integrin inhibitor for the treatment of non-exudative (dry) age-related macular degeneration and diabetic macular edema. Expert Opin Investig Drugs. 2020 Jun;29(6):547-554. doi: 10.1080/13543784.2020.1763953. Epub 2020 May 13. PMID: 32349559.
